Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Edward MacHen

Urology Augusta, GA Medical Doctor

NPI 1255060232 CMS profile 11342004

1447 Harper St, Augusta, GA 30912

Open in the dashboard

General payments

$4,553

56 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward MacHen of Augusta, GA is reported in the CMS Open Payments database as having received $4,553 across 56 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,658 21
2024 General $1,504 17
2023 General $1,247 16
2022 General $144 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward MacHen
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Edward MacHen were reported at $1,658. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Edward MacHen Urology median Middle half National median
2019 $0 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $0 $358 $111–$1,000 $132
2022 $144 $476 $143–$1,263 $149
2023 $1,247 $560 $168–$1,461 $160
2024 $1,504 $563 $170–$1,464 $164
2025 $1,658 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Teleflex LLC $898 9 payments
  2. Boston Scientific Corporation $860 10 payments
  3. Coloplast Corp $739 7 payments
  4. Olympus America Inc. $335 3 payments
  5. Axonics Modulation Technologies, Inc. $251 2 payments
  6. Aroa Biosurgery Incorporated $221 2 payments
  7. PROCEPT BioRobotics Corporation $196 2 payments
  8. Calyxo, Inc. $186 4 payments
  9. Merck Sharp & Dohme Corporation $164 3 payments
  10. Janssen Scientific Affairs, LLC $114 3 payments
  11. Other $590 11 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,553 56 payments
Products named General payments · program years 2022–2025
  1. Titan $418 4 payments
  2. BARRIGEL $383 3 payments
  3. AMS 700 $321 3 payments
  4. Luja Coude $282 2 payments
  5. iTIND System $252 2 payments
  6. Axonics $251 2 payments
  7. AQUABEAM ROBOTIC SYSTEM $196 2 payments
  8. CVAC ASPIRATION SYSTEM $186 4 payments
  9. UROLIFT Interventional Urology $181 3 payments
  10. UROLIFT Interventional Urology $174 2 payments
  11. Other $1,610 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

60

Median for Urology: 1,053

Drug cost

$1,109

Median for Urology: $101,464

Branded share of claims

28.3%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 11 $778
Tamsulosin Hcl Generic 20 $161
Ciprofloxacin Hcl Generic 12 $87
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 17 $83

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OXLUMO
  • Alnylam Pharmaceuticals Inc. $110
$110 — —
ERLEADA
  • Janssen Scientific Affairs, LLC $76
$76 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $38
$38 — —
WELIREG
  • Merck Sharp & Dohme Corporation $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record